Literature DB >> 12570906

[LADA-type diabetes. A category to be taken into account in primary health care].

M Ferré, A Donado, M T García, B Costa.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 12570906      PMCID: PMC7681660          DOI: 10.1016/s0212-6567(03)70663-5

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  5 in total

1.  Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies.

Authors:  T Tuomi; A Carlsson; H Li; B Isomaa; A Miettinen; A Nilsson; M Nissén; B O Ehrnström; B Forsén; B Snickars; K Lahti; C Forsblom; C Saloranta; M R Taskinen; L C Groop
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

2.  Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes.

Authors:  P Zimmet; R Turner; D McCarty; M Rowley; I Mackay
Journal:  Diabetes Care       Date:  1999-03       Impact factor: 19.112

3.  Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA).

Authors:  T Lohmann; K Kellner; H J Verlohren; J Krug; J Steindorf; W A Scherbaum; J Seissler
Journal:  Diabetologia       Date:  2001-08       Impact factor: 10.122

4.  Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA).

Authors:  B Isomaa; P Almgren; M Henricsson; M R Taskinen; T Tuomi; L Groop; L Sarelin
Journal:  Diabetes Care       Date:  1999-08       Impact factor: 19.112

5.  Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency.

Authors:  P Z Zimmet; T Tuomi; I R Mackay; M J Rowley; W Knowles; M Cohen; D A Lang
Journal:  Diabet Med       Date:  1994-04       Impact factor: 4.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.